CompletedNCT05523206
A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome)
Studying Sanfilippo Syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sanguine Biosciences
- Principal Investigator
- Houman Hemmati, MDSanguine Biosciences, Inc.
- Intervention
- No intervention(other)
- Enrollment
- 15 enrolled
- Eligibility
- 13 years · All sexes
- Timeline
- 2022 – 2025
Study locations (1)
- Sanguine Biosciences, Inc., Woburn, Massachusetts, United States
Collaborators
Denali Therapeutics Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05523206 on ClinicalTrials.govOther trials for Sanfilippo Syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06614894An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS IIIOzlem Goker-Alpan
- RECRUITINGPHASE2, PHASE3NCT02716246Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSHUltragenyx Pharmaceutical Inc